JACC:接受心脏移植成年先心病患者的预后研究

2019-11-04 不详 MedSci原创

成年先心病(ACHD)是一个越来越大的人群,本研究的目的旨在评估接受原位心脏移植(OHT)的ACHD患者的预后。本研究纳入分析了196例接受OHT评估的年龄>16岁的ACHD患者(平均年龄31.8岁,27%患者为左心室型,29%为右心室型,44%为单心室型),其中89例(45%)患者列为可以接受OHT,67例(34%)患者最终接受了OHT治疗。患者术后1年的生存率是84.2%,术后5年的生存率为6

成年先心病(ACHD)是一个越来越大的人群,本研究的目的旨在评估接受原位心脏移植(OHT)的ACHD患者的预后。

本研究纳入分析了196例接受OHT评估的年龄>16岁的ACHD患者(平均年龄31.8岁,27%患者为左心室型,29%为右心室型,44%为单心室型),其中89例(45%)患者列为可以接受OHT,67例(34%)患者最终接受了OHT治疗。患者术后1年的生存率是84.2%,术后5年的生存率为69.7%,且不同组别患者之间无明显差异。那些被认为不适合OHT的患者死亡率比那些适合接受OHT的要更高(HR 3.792, p=0.030)。

研究结果显示,被评估做心脏移植的成年先心病患者数量逐年上升,那些不适合做心脏移植的患者预后均较差。


原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854560, encodeId=072818545601b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Nov 15 19:53:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311496, encodeId=78e91311496e1, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Wed Nov 06 10:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326386, encodeId=bc4f1326386aa, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Nov 06 10:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374805, encodeId=30763e48059a, content=威武支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzLQgCrTMdL7iakzu0stzM5re9MHgVvMsICEwRhGlAzdKyyTNNcryycWgADT2IhAu8nUiapnckB3ibg/132, createdBy=509a5220905, createdName=新津孙笑川, createdTime=Mon Nov 04 22:47:40 CST 2019, time=2019-11-04, status=1, ipAttribution=)]
    2019-11-15 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854560, encodeId=072818545601b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Nov 15 19:53:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311496, encodeId=78e91311496e1, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Wed Nov 06 10:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326386, encodeId=bc4f1326386aa, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Nov 06 10:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374805, encodeId=30763e48059a, content=威武支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzLQgCrTMdL7iakzu0stzM5re9MHgVvMsICEwRhGlAzdKyyTNNcryycWgADT2IhAu8nUiapnckB3ibg/132, createdBy=509a5220905, createdName=新津孙笑川, createdTime=Mon Nov 04 22:47:40 CST 2019, time=2019-11-04, status=1, ipAttribution=)]
    2019-11-06 ssnine
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854560, encodeId=072818545601b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Nov 15 19:53:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311496, encodeId=78e91311496e1, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Wed Nov 06 10:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326386, encodeId=bc4f1326386aa, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Nov 06 10:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374805, encodeId=30763e48059a, content=威武支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzLQgCrTMdL7iakzu0stzM5re9MHgVvMsICEwRhGlAzdKyyTNNcryycWgADT2IhAu8nUiapnckB3ibg/132, createdBy=509a5220905, createdName=新津孙笑川, createdTime=Mon Nov 04 22:47:40 CST 2019, time=2019-11-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854560, encodeId=072818545601b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Nov 15 19:53:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311496, encodeId=78e91311496e1, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Wed Nov 06 10:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326386, encodeId=bc4f1326386aa, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Nov 06 10:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374805, encodeId=30763e48059a, content=威武支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzLQgCrTMdL7iakzu0stzM5re9MHgVvMsICEwRhGlAzdKyyTNNcryycWgADT2IhAu8nUiapnckB3ibg/132, createdBy=509a5220905, createdName=新津孙笑川, createdTime=Mon Nov 04 22:47:40 CST 2019, time=2019-11-04, status=1, ipAttribution=)]
    2019-11-04 新津孙笑川

    威武支持

    0

相关资讯

JACC:单动脉冠脉搭桥预后劣于多动脉搭桥

多动脉和单动脉冠脉搭桥(CABG)的收益比较一直存在争议。本研究的目的旨在评估和比较多动脉和单动脉CABG术后的远期生存率、并发症和搭桥的通畅性。本研究共纳入分析了2005-2012年接受CABG治疗的26124名患者,其中3647(14%)名患者接受了多动脉CABG,与多动脉CABG相比,单动脉CABG患者年龄更大(平均68 vs. 61岁; p < 0.001),并发症更多,接受更少的旁

JACC:直流电复律在有左心耳封堵装置的房颤患者中安全可行

直流电复律(DCCV)是一种常见的控制房颤患者心律的手段,但目前尚无DCCV对心内膜左心耳阻塞装置(LAAO)的远期影响。本研究的目的旨在评估DCCV对有LAAO装置患者的可行性和安全性。本研究纳入分析了148例接受DCCV治疗的LAAO患者,平均年龄为72±7岁,女性占41%。所有患者在接受DCCV治疗前接受了经食道心超检测。设备相关血栓发生率为2.7%,患者均服用了口服抗凝药物治疗,并于6-8

“微时代-心纪元 中国冠脉无创功能诊断能力提升项目”新闻发布会成功召开

慢性冠脉综合征(CCS)这一概念在9月刚刚结束的欧洲心脏病学年会被首次提出,2019ESC CCS指南中首先强调了疾病全程管理的概念,冠脉无创功能诊断在全病程管理中的诊断价值日益受到重视。为了进一步推动我国冠心病的管理向全程化、精准化、科学化、规范化发展,提升国内冠脉无创功能诊断的能力,2019年10月12日下午,在北京举办的第三十届长城心脏病学会议(GW-ICC)期间召开了“微时代—心纪元

盘点:JACC十一月第一期一览

1.PCI术后替卡格雷和双重抗凝治疗的比较DOI: 10.1016/j.jacc.2019.08.1038http://www.onlinejacc.org/content/74/18/2278GLOBAL LEADERS临床试验将15991名接受经皮冠脉介入治疗患者随机分成1个月双重抗血小板治疗(DAPT)后接受23个月的替卡格雷治疗和传统的12个月DAPT治疗后12个月阿司匹林治疗组。主要有效

JACC:PCI术后替卡格雷和双重抗凝治疗的比较

GLOBAL LEADERS临床试验将15991名接受经皮冠脉介入治疗患者随机分成1个月双重抗血小板治疗(DAPT)后接受23个月的替卡格雷治疗和传统的12个月DAPT治疗后12个月阿司匹林治疗组。主要有效终点事件是全因死亡、非致死性心梗、非致死性卒中或紧急靶血管血运再生。本研究结果发现,试验组和传统治疗组患者2年后的主要有效终点事件发生率分别是7.14%和8.41%(RR: 0.85; 95%

JACC:房颤消融术后早期死亡风险研究

尽管经导管消融治疗房颤操作相关的死亡率很低,但是患者出院后会出现不良结局。房颤术后的预后评估知之甚少。本研究的目的旨在评估房颤术后早期死亡率的发生率、进展及预测因素。本研究纳入分析了2010-2015年60203名年龄≥18岁的接受房颤消融治疗的患者,最终有0.46%的患者出现早期死亡,其中54.3%发生在再入院时。在2010-2015年期间,导管消融术后每季度的死亡率从0.25%增至1.35%(